JPRN-jRCT2021230013招募中3 期
A multicenter, randomized, open-label, parallel-group study of EN-P11 in patients with enteral tube feeding.
Michio Maruyama0 个研究点目标入组 110 人开始时间: 2023年6月27日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Receiving enteral feeding via enteral tube.
- •2. Patients being hospitalized.
- •3. Aged 18 years or older at the time of obtaining informed consent.
- •4.Written informed consent of free will has been obtained.
排除标准
- •1. History of hypersensitivity to any ingredients of study drugs.
- •2. History of allergy to milk protein.
- •3. Pateints with Ileus.
- •4. No residual intestinal function.
- •5. Severe liver or renal dysfunction (example: acute or chronic renal failure, or cirrhosis).
- •6. Abnormalities in carbohydrate metabolism including severe diabetes mellitus.
- •7. Congenital abnormalities in amino acid metabolism.
- •8. Severe heart disease (example: myocardial infarction), severe hematological disorder (example: aplastic anemia), inflammatory bowel disease, pneumonia, serious diarrhea (example: frequent watery diarrhea), and malignant tumor.
- •9. Pregnant or wish to become pregnant.
- •10. History of resection of gastrointestinal tract (esophagus, stomach or intestines) within 1year before obtaining informed consent , except for slight removal like polyp or appendectomy.
- •11. Taking a diet (regular diet, swallowing control diet, blender diet or paste diet).
- •12. Difficult to take required amount of blood sample for clinical trial.
- •13. Participated in clinical trial or the use of unapproved drugs within 24weeks before obtaining informed consent.
- •14. History of surgery within 4weeks before registration (in case of gastrostomy, minor surgery such as debridement for pressure ulcers, within 2weeks before registration).
- •15. History of fasting for 3or more consecutive days within 4weeks before registration.
- •16. Screening test 1
- •1) Serum AST :100 U/L or more
- •2) Serum ALT :113 U/L or more
- •3) Serum Cre :2 mg/dL or more
- •4) Blood HbA1c :8.0% or more
- •5) Blood WBC :over 9000/uL
- •6) Serum CRP :3.0 mg/dL or higher
- •7) Urinary HCG :positive (not required if menopause has been confirmed, there is no possibility of pregnancy due to surgical procedures in the past, or if it can be confirmed that there has been no sexual activity for more than 1year)
- •17. Screening test 2
- •Body temperature :37.5 degrees Celsius or higher (on registration day).
- •18. Judged by investigator to be excluded.
研究者
相似试验
已完成
不适用
IDPN-2Chronic kidney diseaseJPRN-jRCTs031220296Kanno Yoshihiko40
进行中（未招募）
不适用
Open-label, randomized, active-controlled study of Levetiracetam (LEV) used as monotherapy in patients with Partial-Onset SeizuresEpilepsyPartial SeizuresMedDRA version: 18.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004586-84-Outside-EU/EEACB Pharma SA436
进行中（未招募）
不适用
A randomized, open-label, multicenter, parallel-group study to compare the efficacy, safety and resource utilization of a remifentanil/propofol analgosedation regimen versus a sufentanyl/propofol analgosedation regimen in ventilated patients under intensive medical care with an expected duration of analgosedation of up to 7 daysVentilated patients under intensive medical care with an expected duration of analgosedation of up to 7 daysEUCTR2006-001276-20-DEGlaxoSmithKline GmbH & Co. KG164
进行中（未招募）
不适用
An open-label, randomized, multicenter, parallel-group study to demonstrate correction of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis - CORDATUSChronic renal anemiaMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaEUCTR2006-001434-41-HUF. Hoffmann-La Roche Ltd300
进行中（未招募）
不适用
An open-label, randomized, multicenter, parallel-group study to demonstrate correction of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney disease who are not on dialysis - CORDATUSEUCTR2006-001434-41-BEF. Hoffmann-La Roche Ltd300